Literature DB >> 26091306

Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis.

Zhiyong Yang1, Yongrong Zhang, Tuxiong Huang, Hanping Feng.   

Abstract

Clostridium difficile TcdB harbors a glucosyltransferase that targets host Rho GTPases. However, the role of the enzyme activity in the induction of host intestinal disease has not been demonstrated. In this study, we established a mouse acute intestinal disease model by cecum injection of wild type and glucosyltransferase-deficient TcdB and a chronic model by delivering toxin intraluminally via engineered surrogate host Bacillus megaterium. We demonstrated, for the first time, that the glucosyltransferase activity of TcdB is essential for inducing disease symptoms and intestinal pathological responses that resemble human disease, highlighting the importance of targeting toxin glucosyltransferase activity for future therapy.

Entities:  

Keywords:  Clostridium difficile; glucosyltransferase; pathogenesis; toxin

Mesh:

Substances:

Year:  2015        PMID: 26091306      PMCID: PMC4615278          DOI: 10.1080/19490976.2015.1062965

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  11 in total

Review 1.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

2.  Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.

Authors:  E Chaves-Olarte; M Weidmann; C Eichel-Streiber; M Thelestam
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.

Authors:  Shan Li; Lianfa Shi; Zhiyong Yang; Yongrong Zhang; Gregorio Perez-Cordon; Tuxiong Huang; Jeremy Ramsey; Numan Oezguen; Tor C Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

4.  Glucosylation of Rho proteins by Clostridium difficile toxin B.

Authors:  I Just; J Selzer; M Wilm; C von Eichel-Streiber; M Mann; K Aktories
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

5.  A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.

Authors:  Haiying Wang; Xingmin Sun; Yongrong Zhang; Shan Li; Kevin Chen; Lianfa Shi; Weijia Nie; Raj Kumar; Saul Tzipori; Jufang Wang; Tor Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

6.  In vivo physiological and transcriptional profiling reveals host responses to Clostridium difficile toxin A and toxin B.

Authors:  Kevin M D'Auria; Glynis L Kolling; Gina M Donato; Cirle A Warren; Mary C Gray; Erik L Hewlett; Jason A Papin
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

7.  Pyknotic cell death induced by Clostridium difficile TcdB: chromatin condensation and nuclear blister are induced independently of the glucosyltransferase activity.

Authors:  Katharina Wohlan; Sebastian Goy; Alexandra Olling; Sangar Srivaratharajan; Helma Tatge; Harald Genth; Ralf Gerhard
Journal:  Cell Microbiol       Date:  2014-08-04       Impact factor: 3.715

8.  The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins.

Authors:  I Just; M Wilm; J Selzer; G Rex; C von Eichel-Streiber; M Mann; K Aktories
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

9.  Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism.

Authors:  Nicole M Chumbler; Melissa A Farrow; Lynne A Lapierre; Jeffrey L Franklin; David B Haslam; David Haslam; James R Goldenring; D Borden Lacy
Journal:  PLoS Pathog       Date:  2012-12-06       Impact factor: 6.823

10.  Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium.

Authors:  Guilin Yang; Boping Zhou; Jufang Wang; Xiangyun He; Xingmin Sun; Weijia Nie; Saul Tzipori; Hanping Feng
Journal:  BMC Microbiol       Date:  2008-11-06       Impact factor: 3.605

View more
  11 in total

1.  Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.

Authors:  Hua Yu; Kevin Chen; Ying Sun; Mihaela Carter; Kevin W Garey; Tor C Savidge; Sridevi Devaraj; Mary Elizabeth Tessier; Erik C von Rosenvinge; Ciaran P Kelly; Marcela F Pasetti; Hanping Feng
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.

Authors:  Yongrong Zhang; Zhiyong Yang; Si Gao; Therwa Hamza; Harris G Yfantis; Michael Lipsky; Hanping Feng
Journal:  Anaerobe       Date:  2017-10-12       Impact factor: 3.331

Review 3.  Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics.

Authors:  Shannon L Kordus; Audrey K Thomas; D Borden Lacy
Journal:  Nat Rev Microbiol       Date:  2021-11-26       Impact factor: 78.297

4.  Defective mutations within the translocation domain of Clostridium difficile toxin B impair disease pathogenesis.

Authors:  Therwa Hamza; Zhifen Zhang; Roman A Melnyk; Hanping Feng
Journal:  Pathog Dis       Date:  2015-10-26       Impact factor: 3.166

Review 5.  Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.

Authors:  Yongrong Zhang; Hanping Feng
Journal:  Pathog Dis       Date:  2016-04-04       Impact factor: 3.166

Review 6.  Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.

Authors:  Stefano Di Bella; Paolo Ascenzi; Steven Siarakas; Nicola Petrosillo; Alessandra di Masi
Journal:  Toxins (Basel)       Date:  2016-05-03       Impact factor: 4.546

7.  Analysis of TcdB Proteins within the Hypervirulent Clade 2 Reveals an Impact of RhoA Glucosylation on Clostridium difficile Proinflammatory Activities.

Authors:  Carlos Quesada-Gómez; Diana López-Ureña; Nicole Chumbler; Heather K Kroh; Carolina Castro-Peña; César Rodríguez; Josué Orozco-Aguilar; Sara González-Camacho; Alexandra Rucavado; Caterina Guzmán-Verri; Trevor D Lawley; D Borden Lacy; Esteban Chaves-Olarte
Journal:  Infect Immun       Date:  2016-01-11       Impact factor: 3.441

8.  Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota.

Authors:  John Tam; Therwa Hamza; Bing Ma; Kevin Chen; Greg L Beilhartz; Jacques Ravel; Hanping Feng; Roman A Melnyk
Journal:  Nat Commun       Date:  2018-12-07       Impact factor: 14.919

9.  Cysteine Protease-Mediated Autocleavage of Clostridium difficile Toxins Regulates Their Proinflammatory Activity.

Authors:  Yongrong Zhang; Shan Li; Zhiyong Yang; Lianfa Shi; Hua Yu; Rosangela Salerno-Goncalves; Ashley Saint Fleur; Hanping Feng
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-02-09

10.  The glucosyltransferase activity of C. difficile Toxin B is required for disease pathogenesis.

Authors:  Terry W Bilverstone; Megan Garland; Rory J Cave; Michelle L Kelly; Martina Tholen; Donna M Bouley; Philip Kaye; Nigel P Minton; Matthew Bogyo; Sarah A Kuehne; Roman A Melnyk
Journal:  PLoS Pathog       Date:  2020-09-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.